Down syndrome in association with features of the androgen insensitivity syndrome

R M Viner, N Shimura, B D Brown, A J Green, I A Hughes

Abstract
Three cases of Down syndrome (DS) are reported in association with features of the androgen insensitivity syndrome (AIS). All were 47,XY, +21 and reared as females. One case had a normal female phenotype, and two cases showed minimal clitoromegaly and labial fusion. Minor genital underdevelopment has been reported as common in males with DS; however, AIS has not previously been associated with DS. Androgen binding studies in genital skin fibroblasts were normal in two cases and in the 46,XY brother of the third who has perineal hypospadias. Mutation screening of the androgen receptor (AR) gene by PCR-SSCP was normal in all cases. Normal androgen binding and the absence of an identified mutation in the coding region of the AR gene is very unusual in AIS, particularly in the complete form. This finding suggests the operation of hitherto unrecognised genes on chromosome 21 with a role in androgen response and sex differentiation. (J Med Genet 1996;33:574-577)

Key words: Down syndrome; androgen insensitivity; sex determination.

The association of Down syndrome (DS) with the androgen insensitivity syndrome (AIS) has not previously been reported. DS is a common genetic disorder arising from trisomy 21 usually secondary to maternal non-disjunction during meiosis, or more rarely from de novo or inherited unbalanced translocations. The androgen insensitivity syndromes are rare X linked single gene disorders of phenotypic sexual development associated with a male (46,XY) karyotype. AIS is characterised by a female or ambiguous genital phenotype in a 46,XY male with normal testicular histology and normal testosterone production. Cases show either complete (CAIS) or partial (PAIS) insensitivity to androgen action. The former presents with a normal female phenotype whereas the latter presents in a spectrum from apparently virilised females to undervirilised males.

We report three cases of Down syndrome, two with features of a PAIS phenotype based on minimal clitoral enlargement, and one with a CAIS phenotype. Androgen insensitivity has not previously been reported in Down syndrome. However, studies have reported impaired fertility, and mildly impaired gonadal function in a high proportion of males with DS. Increased incidence of anatomical anomalies such as microopeni, hypospadias, cryptorchidism, small testes, and delayed or poor pubertal development have been reported in institutionalised cases of DS. Two larger studies of male DS cases managed outside institutions differed on the nature of sexual development in DS. Peuschel et al reported normal pubertal gonadal development and secondary sex characteristics, whereas Hsiang et al, while reporting no increased incidence of genital anomalies with respect to the normal population, nevertheless found penile size and testicular volume to be reduced in comparison to population norms.

Male pseudohermaphroditism (incomplete external genital development) in association with DS has been reported in only two previous cases. The first case was a child with a mosaic karyotype 47,XY, +21/46,XY, +21 in whom testes, bifid scrotum, perineal hypospadias, and female internal genitalia were shown. Mosaicism for an XO cell line would explain the ambiguous phenotype in this case. The second case was 47,XY, +21 with normal testes, fused labioscrotal folds, enlarged phallus, perineal urethral opening, vaginal orifice, and absent internal female genitalia by vaginoscopy. Serum testosterone values were not determined, but 24 hour urinary secretion of androsterone metabolites was normal. The case is suggestive of AIS, but the diagnosis cannot be substantiated without information on testosterone production and metabolism.

No studies of androgen, metabolism or androgen receptor binding have been reported in DS. Major genital anomalies have not been reported by either of two large studies of DS males. Histology of the testis in DS usually shows markedly decreased spermatogenesis. Sparse or poor development of androgen dependent hair (pubic, axillary, beard) has been reported in DS. Testosterone levels have been found to be normal in DS men. However, the finding of frequently raised FSH and LH levels has been interpreted as evidence of mild gonadal dysgenesis in DS. In the only study of DS male children, Hsiang et al reported that five of 27 had raised LH levels, and eight of 27 showed raised FSH levels.

AIS is a phenotypically heterogeneous syndrome, and the known molecular defects in the androgen receptor (AR) responsible for androgen insensitivity are diverse in nature. Studies of androgen binding in genital skin fibroblasts of AIS patients have defined patients as either androgen receptor positive or AR negative. The majority of CAIS patients are receptor negative. In contrast, no clear cut
relationship between clinical phenotype and AR binding exists in PAIS patients; the majority of cases show normal receptor binding, although a small subset show qualitative abnormalities in AR binding. When binding is negative or qualitatively abnormal, mutations are invariably identified in the exons encoding the ligand binding domain of the AR gene, whereas normal AR binding in CAIS is invariably associated with mutations affecting the DNA binding region. A number of cases, particularly PAIS, show normal AR binding and no detectable abnormality in the AR gene. This finding suggests that hitherto unrecognised genes may be involved in the regulation of androgen sensitivity in humans.

Case reports
Cases were drawn from an AIS database established at the Department of Paediatrics, University of Cambridge, partly as a result of a UK wide survey of AIS undertaken through the auspices of the British Paediatric Association Surveillance Unit. Ascertainment of the cases was based upon postnatal chromosomal analysis performed because of clinical features of Down syndrome. Cases 1 and 2 (figure) had slightly abnormal genitalia noted at birth, while case 3 had normal female genitalia (table 1). All cases were non-disjunctional trisomy 21 with karyotypes 47,XY,+21. A diagnosis of AIS was based upon male karyotype and the results of subsequent investigations. Two cases on balance had features consistent with a PAIS phenotype but only very minimal signs of virilisation, and one case had a typical CAIS phenotype.

Investigations
These included measurement of androgen production and metabolism after HCG stimulation, basal gonadotrophin concentrations, testicular histology, assessment of AR binding in genital skin fibroblasts, and DNA analysis.

Normal androgen production and metabolism, and normal testicular histology was found in cases 1 and 2 (table 2). Investigation of case 3 was limited by the associated complex cardiac problems. Interestingly, a 46,XY sib had isolated perineal hypospadias so a genital skin fibroblast line was established at the time of surgical repair to measure AR binding. Androgen binding activity was measured by a whole cell binding assay using genital skin fibroblasts. Androgen binding was normal in cases 1 and 2, and in the 46,XY sib of case 3 (table 3). All three cases were reared as females. Bilateral gonadectomy was performed on case 1 at 11 years, and bilateral gonadectomy and vulvovaginoplasty on case 2 at 2 months of age. None of the cases has received androgen or oestrogen therapy.

DNA was obtained in case 1 and the sib of case 3 from genital skin fibroblasts and from peripheral blood lymphocytes in cases 2 and 3. Mutation screening of the AR gene was carried out by PCR-single strand conformation polymorphism (SSCP) analysis of DNA as previously published. All eight exons of the AR gene which encode the ligand binding, DNA binding, and transcriptional activation domains were analysed. There was no evidence of a band shift to indicate the presence of an AR gene mutation in any of the three cases; in particular the two exons encoding the DNA binding domain of the AR were normal.

Table 1: Clinical features of AIS cases

<table>
<thead>
<tr>
<th>Date of birth</th>
<th>Genitalia</th>
<th>Phenotype</th>
<th>Gonads</th>
<th>Clitoromegaly</th>
<th>Urethral opening</th>
<th>Scrotum/labia</th>
<th>Vaginal orifice</th>
<th>Uterus</th>
<th>Associated conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td>29.12.84</td>
<td>PAIS</td>
<td>Nil</td>
<td>Mild</td>
<td>Mild</td>
<td>Perineal</td>
<td>Unfused</td>
<td>Present</td>
<td>Absent</td>
<td>Nil</td>
</tr>
<tr>
<td>1.7.94</td>
<td>PAIS</td>
<td>Nil</td>
<td>Mild</td>
<td>Mild</td>
<td>Perineal</td>
<td>Unfused</td>
<td>Present</td>
<td>Absent</td>
<td>Nil</td>
</tr>
<tr>
<td>14.9.78</td>
<td>CAIS</td>
<td>Nil</td>
<td>Mild</td>
<td>Mild</td>
<td>Perineal</td>
<td>Unfused</td>
<td>Present</td>
<td>Absent</td>
<td>Nil</td>
</tr>
</tbody>
</table>

Table 2: Endocrine investigations and gonadal histology

<table>
<thead>
<tr>
<th>HCG simulation test</th>
<th>Case 1</th>
<th>Case 2</th>
<th>Case 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>HCG single dose</td>
<td>500</td>
<td>500</td>
<td>Not done</td>
</tr>
<tr>
<td>Post</td>
<td>12</td>
<td>7.8</td>
<td>1-0</td>
</tr>
<tr>
<td>Pre</td>
<td>28</td>
<td>9.4</td>
<td>Not done</td>
</tr>
<tr>
<td>Testosterone (nmol/l)</td>
<td>2-2</td>
<td>0-4</td>
<td>5-4</td>
</tr>
<tr>
<td>Dihydrotestosterone (nmol/l)</td>
<td>1-0</td>
<td>0-53</td>
<td>1-0</td>
</tr>
<tr>
<td>Androstenedione (nmol/l)</td>
<td>2-3</td>
<td>2-8</td>
<td>Not done</td>
</tr>
<tr>
<td>LH (U/l)</td>
<td>7.2</td>
<td>2.8</td>
<td>&lt;1</td>
</tr>
<tr>
<td>FSH (U/l)</td>
<td>2.3</td>
<td>5.4</td>
<td>1-0</td>
</tr>
<tr>
<td>Urinary steroid profile</td>
<td>Not done</td>
<td>Normal</td>
<td>Not done</td>
</tr>
<tr>
<td>Histology</td>
<td>Normal testes</td>
<td>Normal testes</td>
<td>Not done</td>
</tr>
</tbody>
</table>
Table 3  Androgen binding in genitalic skin fibroblasts

<table>
<thead>
<tr>
<th>Case 1</th>
<th>Case 2</th>
<th>Case 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bmax (normal range 1342±8±419 x 10⁻¹⁰ mol/μg DNA)</td>
<td>1136</td>
<td>949</td>
</tr>
<tr>
<td>Kd (normal range 1-08±0-252 x 10⁻¹⁰ mol/l)</td>
<td>0-71</td>
<td>1-0</td>
</tr>
</tbody>
</table>

Discussion

Three cases of Down syndrome with a predominantly female phenotype are described with a 47,XY, +21 karyotype, normal testosterone production and metabolism, and normal testicular histology in two of three cases. There was no evidence of a defect in steroid biosynthesis based on the adequate androgen response to HCG stimulation. Furthermore, gonadal dysgenesis possibly associated with a defect in a testis determining gene such as SRY,11 DAX-1,19 20 or WT-1,17 is unlikely in view of the normal androgen response to HCG and normal testicular histology. Even though all three cases had features consistent with the diagnosis of AIS, no defect in the AR gene was detected by screening with PCR-SSCP analysis. This technique is a reliable screen based upon our previous work,27 and subsequently confirmed by direct sequence analysis (H R Davies, personal observation).

This cluster is possibly a chance occurrence. However, the finding of normal androgen binding and normal AR gene in one case with a typical CAIS phenotype and the other two cases at the extreme female end of the PAIS phenotypic spectrum is very uncommon,13 14 and suggests that this cluster is more than mere coincidence. While it is interesting that a 46,XY sib of case 3 who has complete sex reversal also has a severe genital anomaly, the cause in this instance is clearly unrelated to an extra chromosome 21. The finding of cases with chromosomal anomalies in association with disorders of sex differentiation provides potential evidence regarding the presence and action of genes postulated to regulate androgen activity.16

The presence of DS in these cases suggests that hitherto unrecognised genes on chromosome 21 may be involved in the pathway of sex differentiation. Chromosome 21 carries genes implicated in Alzheimer disease, familial amyotrophic lateral sclerosis, cytosinuhrinia, and acute megakaryocytic leukaemia.22 The common association of congenital heart disease and duodenal stenosis in DS has led researchers to postulate the existence of genes on chromosome 21 that are important in the development of the heart and the gastrointestinal system in both DS and normal subjects.23 No genes on chromosome 21 are are present known to be implicated in sex differentiation or androgen responsiveness. However, the common findings of minor undervirilisation in males with DS supports the hypothesis that genes on chromosome 21 may have a role in sex differentiation and androgen response. It is likely that features consistent with AIS may be under-reported in DS, as minor genital anomalies such as mild clitoromegaly or simple hypospadias are more likely to be disregarded in DS than in the general population.

One possible explanation is the presence of an SRY box (Sox) gene on chromosome 21, given the recent finding of an association between the Sox-9 gene and sex reversal in campomelic dysplasia.24 Sox genes are closely related to the SRY gene that determines testis development in mammals. SRY exerts its function through transcriptional control of unidentified genes “downstream” in the testis development pathway, and defects in SRY have been found to result in XY females with gonadal dysgenesis.18 24 It is postulated that, like SRY, Sox genes may act as transcription factors in sex development control pathways, and some Sox genes have been identified as involved in sex differentiation.18 The phenotypic spectrum from a normal female phenotype and minor virilisation as described in these cases to the minor undervirilisation commonly reported in male DS may be explained by allelic heterogeneity in the spectrum of genes acting on the trisomic chromosomes.18 25 Further work is needed to characterise the defect in gonadal function in male DS patients and to determine whether chromosome 21 plays a role in sex determination.

We are grateful to the following persons for providing clinical information relevant to the cases: Dr V Martin, Consultant Paediatrician, Perth Royal Infirmary, Perth; Dr J A Sill, Consultant Paediatrician, St Helens and Knowsley Hospital, Prescot; Merseyside; Dr P J Howard, Consultant Clinical Scientist, Merseyside and Cheshire Regional Cytogenetics Unit. Dr N Shimizu was supported by a grant from Eli Lilly, Japan, and the work was funded by the Wellcome Trust. The help of the British Paediatric Association Surveillance Unit in identifying cases for further study is gratefully appreciated.

17 Batch JA, Williams DM, Davies HR, et al. Androgen receptor
19 Zanaria E, Muscatelli F, Bardi B, et al. An unusual member of the nuclear hormone receptor superfami-

Down syndrome in association with features of the androgen insensitivity syndrome.

R M Viner, N Shimura, B D Brown, A J Green and I A Hughes

*J Med Genet* 1996 33: 574-577
doi: 10.1136/jmg.33.7.574

Updated information and services can be found at:
http://jmg.bmj.com/content/33/7/574

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/